LIVER FIBROSIS TREATMENT MARKET ANALYSIS

Liver Fibrosis Treatment Market, by Treatment Type (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, and Others), by Condition (Chronic Liver Diseases, Hepatitis C, and Nonalcoholic Steatohepatitis), by Distribution Channel (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI2320
Pages :168
Formats :
Excel and PDF
Industry : Pharmaceutical

Liver Fibrosis Treatment MarketSize and Trends

Figure 1. Global Liver Fibrosis Treatment Market Share (%), by End User, 2022

Global liver fibrosis treatment market is estimated to be valued at US$ 14.7 billion in 2022 and is expected to exhibit a CAGR of 10.8% during the forecast period (2022-2030).

Funding initiatives by various private research organizations to conduct research related to development of treatment for liver fibrosis and other fatty liver diseases is expected to drive growth of the liver fibrosis treatment market.

Increasing research by various private research organizations to conduct research related to development of treatment for liver fibrosis and other fatty liver disease is expected to drive growth of the liver fibrosis treatment market. For instance, in August 2018, College of Science at Virginia Tech and Department of Pharmacology at the University of Virginia, based in the U.S. received US$ 400,000 grant from the Virginia Biosciences Health Research Corporation (VBHRC) with US$ 800,000 matching funds from Continuum Biosciences, Inc. This grant along with matching funds would help researchers to develop drugs to treat nonalcoholic steatohepatitis (NASH).